Two genomic studies could yield more effective, less toxic immunotherapies

AI background business technology, digital transformation

Mnemo Therapeutics, a biotechnology company developing transformational immunotherapies, has announced publication of two scientific studies developed at Institut Curie, its closest academic collaborator, in the journal Science Immunology. The publications reveal TE-exon splicing junctions act as a source of novel recurrent, cancer-specific targets and have potential implications for developing more effective and less toxic immunotherapies. The findings presented further validate Mnemo’s antigen discovery platform, which is a critical driver of the company’s cell therapy pipeline.

A new tumor-suppressive gene that boosts personalized treatment response in breast cancer

Previous article

Study identifies an antibody candidate for treating serious liver disease

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations